Fintel on MSN18h
Leerink Partners Downgrades Lexicon Pharmaceuticals (LXRX)
Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...
Business Wire20h
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the ...